Disease Landscape and Forecast Insights

The chronic obstructive pulmonary disease (COPD) therapy market continues to suffer from the absence of any agents that can reverse disease progression and repair lung tissue. Smoking cessation is…

Thechronic obstructive pulmonary disease(COPD) market is continuing its gradual shift away from long-acting beta2 agonist/inhaled corticosteroid fixed-dose combinations(LABA/ICSFDCs) toward LABA/…

DRG publishes a new primary market research report tracking awareness, trial, and use of Mylan’s Wixela Inhub, a therapeutic equivalent to Advair.  

Mylan’s salmeterol/fluticasone propionate generic, Wixela Inhub, is the first substitutable generic for GSK’s Advair, one of the top-selling therapies for asthma and COPD. Although other…

MARKET OUTLOOK Long-acting beta2 agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) are gaining traction in the COPD market, and both LAMAs and LABA/…

MARKET OUTLOOK The COPD market is continuing its gradual shift away from LABA/ICSFDCs toward LABA/LAMA FDCs, but current and emerging generics will have a significant impact on this trend…

MARKET OUTLOOK COPD is a progressive inflammatory respiratory tract and lung disease characterized by airflow obstruction and decreased lung function. The COPD market continues to suffer from…

The chronic obstructive pulmonary disease (COPD) market is experiencing increased competition as newer combination therapies vie with long-marketed stalwarts Spiriva, Advair, and Symbicort. Current…

The COPD therapy market is a crowded space in which several LAMAs (e.g., Boehringer Ingelheim’s Spiriva, AstraZeneca’s Tudorza), LABA/ICSFDCs (e.g., GlaxoSmithKline’s Advair and Breo,…

MARKET OUTLOOK Long-acting beta2 agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) are beginning to gain traction in the COPD market, and both LAMAs and…

Current market-leading therapies in the U.S. COPD market will face challenges from emerging drugs, especially generic versions of Spiriva, Symbicort, and Advair. Surveyed physicians often report …

Most patients with chronic obstructive pulmonary disease (COPD) in the five European countries under study receive treatment shortly after diagnosis. The progressive nature of the disease results…